ATLANTA– Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced receipt of a “Study May Proceed” letter from the U.S. Food and Drug Administration (“FDA”) for the initiation of study AL001-PTSD01, a Phase IIA clinical study of AL001 for treatment of patients with PTSD.
“We are grateful to receive this timely, favorable response from the FDA to initiate our first Phase IIA clinical study of AL001 for PTSD. Although lithium does not have an FDA-approved indication for PTSD, it has been prescribed off-label for this purpose for decades,” said Stephan Jackman, Chief Executive Officer of Alzamend. “If we can develop a next-generation lithium product (AL001) that would not routinely require therapeutic drug monitoring (‘TDM’), it would constitute a major improvement over current lithium-based treatments and positively impact the 9 million Americans afflicted with PTSD. We are advancing the process and expect that the first patient will be dosed in the first quarter of 2024. We have now received ‘Study May Proceed’ letters from the FDA during the last three months for Phase IIA clinical studies of AL001 for treatment of patients with BD, MDD and PTSD.”
